Thallion Pharmaceuticals Inc.
TSX : TLN

Thallion Pharmaceuticals Inc.

July 10, 2007 15:02 ET

Notice of Thallion Pharmaceuticals Inc. Fiscal 2007 Second Quarter Conference Call

- Second quarter financial results to be released on July 12, 2007 -

MONTREAL, QUEBEC--(Marketwire - July 10, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) will release its second quarter fiscal results for 2007 on Thursday, July 12, 2007 at 4:00 p.m. Eastern Time. The announcement will be followed by a conference call at 4:30 p.m. Eastern Time, hosted by Mr. Lloyd M. Segal, Chief Executive Officer and Mr. Michael Singer, Chief Financial Officer. A question and answer session will follow the formal presentation.



CONFERENCE CALL DETAILS

DATE: July 12, 2007

TIME: 4:30 pm Eastern Time

DIAL IN NUMBER: 416-644-3415 or 800-732-9303

REFERENCE NUMBER: 21238965

TAPED REPLAY: 416-640-1917 or 877-289-8525


A live audio webcast of the conference call, complete with a slide presentation, will be available by visiting the Company's website at www.thallion.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX:TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion's clinical-stage programs include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anticancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Thallion Pharmaceuticals was formed on March 14, 2007 by the amalgamation of Ecopia BioSciences Inc. and Caprion Pharmaceuticals Inc. Additional information about the Company can be obtained at www.thallion.com.

Contact Information